10 February 2016 - Novartis has criticised some of the proposed changes to the way in which the UK Cancer Drugs Fund is operated, as the consultation period on the proposals come to an end, saying a number of the suggestions are “not workable”.

For more details, go to: http://www.pharmafile.com/news/502856/novartis-says-cdf-proposals-place-unreasonable-risk-pharma??utm_medium=nl&utm_source=internal&mkt_tok=3RkMMJWWfF9wsRokuqzJcu%2FhmjTEU5z17%2BkqUKG3iokz2EFye%2BLIHETpodcMSMZiNLDYDBceEJhqyQJxPr3HJdQN18R7RhHnDg%3D%3D